Modality
Multispecific
MOA
JAK1i
Target
Menin
Pathway
Lipid Met
LGSAS
Development Pipeline
Preclinical
~Dec 2019
→ ~Mar 2021
Phase 1
~Jun 2021
→ ~Sep 2022
Phase 2
Dec 2022
→ Jun 2028
Phase 2Current
NCT05492969
826 pts·LGS
2022-12→2027-12·Completed
NCT05523737
982 pts·LGS
2025-09→2028-06·Active
1,808 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-181.7y awayPh2 Data· LGS
2028-06-242.2y awayPh2 Data· LGS
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Complet…
P2
Active
Catalysts
Ph2 Data
2027-12-18 · 1.7y away
LGS
Ph2 Data
2028-06-24 · 2.2y away
LGS
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05492969 | Phase 2 | LGS | Completed | 826 | LiverFat |
| NCT05523737 | Phase 2 | LGS | Active | 982 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα |